Testing PORPHYSOMES with 64Cu-PORPHYSOMES for gynecological cancers

Exclusion

• −History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.
• −Patient is a candidate for therapy with curative intent.
• −Patient has a contraindication to PET/CT imaging, including, but not limited to, phobias associated with imaging (e.g. claustrophobia) and those who cannot lie still in the supine position for at least 20 minutes.
• −Patients receiving nuclear medicine scans with other radiopharmaceutical agents (ex: 18F-FDG or other) during the study's exclusionary period will be excluded from the study.
• −Patients with known myelodysplastic syndrome/acute myeloid leukemia.
• −Treatment with an investigational drug within 15 days prior to study registration.
• −Patients with a known active COVID-19 infection at the time of registration/enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →.
• −Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the InvestigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more → would make the subject inappropriate for entry into this study.
• −Uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• −Unresolved toxicity \> CTCAE grade 1 from previous anti-cancer therapies, including radiotherapy, with exception.
• −Retinopathy ≥ grade 2.
• −Patients with porphyria.
• −Patients that have undergone a splenectomy.
• −Pregnant or breast-feeding women.
• −Patients must not receive any other oncological treatments, including chemotherapy and/or radiation, within 2 weeks before starting study drug administration (and for 28 days after study drug administration).